This column offers a deeper look into especially innovative or entrepreneurial biopharma companies, individuals, or institutions through our special lens — lessons learned, actionable info, benchmarking, best practices, etc.
Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.
Karen Aiach had no background in healthcare when her young daughter received a diagnosis of a rare form of Sanfilippo syndrome. Aiach built her company, Lysogene, to create the world’s first treatment for the terrible disease.
The unusual story of how Apellis was formed and what led it to target C3, the central factor in the innate-immunity complement system, to treat autoimmune diseases — starting with the ultra-rare blood condition, PNH.
Reata refused to take what seemed like a dead-end trial as a losing proposition. Instead, the company went to work mining the trial for the very insights that subsequently saved it.
Cydan is using a new business model in which they challenge the ways companies dealt with orphan drugs in the past.
In this series on "Life Science Leadership In Action," we discuss PolarityTE, which focuses on regenerating lost tissues in their original complex forms.
Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.
Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.
Why shouldn’t our mitochondria want us to live long, prospering in good health? Why shouldn’t they — as symbiotic microbes turned cellular organelles with their own mini-genomes — carry genes that help ensure our healthful survival?
Clinical challenges lurk all along the pathway for any company developing new vaccine candidates and technology — and that goes at least twice for Novavax. As we go to press with this, the company is dealing with an anxious investment community about the “failed” Phase 3 trial of its RSV F vaccine in older adults, for protection against respiratory syncytial virus (RSV). (See “Press-Time Thunder.”)
Lee Jones, the CEO and cofounder of Rebiotix, describes building the company in an “of course, this is how you do it” manner. The larger issue — whether the company’s Microbiota Restoration Therapy (MRT) platform will succeed in a somewhat besieged field — can only be resolved over time. But it will most likely be biology that decides the matter, not the typical lack of clear direction or organization that plagues so many biopharma startups.
Suffocation seldom gets the credit it deserves for causing death in so many conditions — from sleep apnea to heart failure to drug overdose. But if you view the large variety of those cases at a higher resolution, you will see “respiratory failure” as the common final, fatal effect.
I have never seen such a bold and ambitious approach to treating, dare I say healing, one of the worst injuries anybody can sustain — a spinal cord injury. The story of InVivo’s development of a tiny scaffold inserted into the injury site merits attention in “The Enterprisers” both for its ambitious goal and its means for reaching it.
A simple twist of fate is all it takes to knock you off your original track. In the case of the company that would be reborn as Amarantus, it was another company’s bad luck in the clinic that ended its first push for partnering and funding.
Rob Wright explores what makes a serial entrepreneur tick (part 1) via Brad Margus, cofounder and CEO of Cerevance. Margus may have started out in the shrimping business, but he went on to found a disease specific 501c3 nonprofit, ultimately leading him to found three different biopharmaceutical companies.
In part 2 of what makes serial entrepreneur Brad Margus tick, Rob Wright explores the various lessons learned by Margus during the founding of multiple biopharmaceutical companies, along with an update on the 501c3 nonprofit organization he helped to cofound, the A-T Children’s Project.
John Oyler, cofounder and CEO of BeiGene, a 9-year-old global biopharmaceutical company today valued at more than $8.5 billion, discusses the importance of having a “rock star” scientist cofounder in Xiandong Wang, Ph.D., and his impact on recruiting top talent.
The little known story of an immigrant couple making a $15 million difference for U.S. veterans.
A Life Science Leader reader shares their thoughts on why the biopharmaceutical industry’s reputation is so dismal, but also proposes solutions for how to repair it.